Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has announcements × tagraxofusp × Clear all
NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Stemline Therapeutics, Inc.

Phase 1/2 Completed
138 enrolled 23 charts 2 FDA
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡